Cabergoline
United States Pharmacopeia (USP) Reference Standard
Manufacturer: Sigma Aldrich
CAS Number: 81409-90-7
Synonym(S): Cabergoline, 1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 125 MG | 1084306-125-MG | In Stock | ₹ 3,75,681.63 |
1084306 - 125 MG
In Stock
Quantity
1
Base Price: ₹ 3,75,681.63
GST (18%): ₹ 67,622.693
Total Price: ₹ 4,43,304.323
grade
pharmaceutical primary standard
API family
cabergoline
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1
InChI
1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChI key
KORNTPPJEAJQIU-KJXAQDMKSA-N
Gene Information
human ... DRD2(1813)
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
Sigma Aldrich Fine Chemicals Biosciences Cabergoline European Pharmacopoeia (EP) Reference Standard | 81409-90-7 | MFCD00867887 | | -- | ₹ 17,007.90 | ||
Sigma Aldrich Fine Chemicals Biosciences Cabergoline >=98% (HPLC) | 81409-90-7 | MFCD00867887 | 50MG | -- | ₹ 1,06,070.20 | ||
Cabergoline | -- | ₹ 14,267.35 | ||
81409-90-7 | Cabergoline | -- | ₹ 3,560.00 - ₹ 55,269.00 |
Related Products
Description
- General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
- Biochem/physiol Actions: Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
- Analysis Note: These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
- Other Notes: Sales restrictions may apply.
SAFETY INFORMATION
Pictograms
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral - Lact.
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable